The Changing Landscape of IBD: Emerging Concepts in Patient Management

A Multimedia Educational eHealth Source™

Activity Details

Free CME

1.5 AMA PRA Category 1 Credits™

Released: January 17, 2019
Expires: January 17, 2020

1 hour, 30 mins to complete

Jointly Provided by

Target Audience

This activity is intended for clinical gastroenterologists and specialist NP/PAs involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives

Evaluate disease risk and identify individuals who are likely to benefit from biologic or targeted synthetic therapy
Tailor management regimens for patients with inflammatory bowel disease (IBD) using a treat-to-target approach that reflects disease severity, treatment goals, therapeutic responses, and patient preferences
Partner with patients to provide IBD disease state education, promote shared clinical decision-making, encourage self-management efforts, and personalize long-term care
Discuss the cytokine networks underlying IBD pathophysiology, with a focus on newer mechanisms of action
Review mechanisms of current and novel non–tumor necrosis factor biologic and targeted synthetic therapies for the treatment of IBD

Activity Description

This activity presents an in-depth review of IBD patient care in moderate to severe disease, including immunopathogenesis of IBD, existing management options, shared decision-making, and investigational targeted therapies, via text and concise video commentaries provided by noted IBD experts

Statement of Educational Need

In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs)—ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.¹ As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms.¹

Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.

Reference

1. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.

Agenda

Chapter 1: Assessment Strategies and Treatment Goals in IBD
Chapter 2: Best Practices in Tailoring Treatment of Moderate and Severe IBD
Chapter 3: Evolving Concepts in IBD Pathophysiology
Chapter 4: Targeted Mechanism-Based Therapies for IBD on the Horizon

Faculty

Raymond K. Cross, MD, MS
Professor of Medicine
Director, Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Co-Director, Digestive Health Center
University of Maryland Medical Center
Baltimore, MD

Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Raymond K. Cross, MD, MS

Consultant/Independent Contractor: AbbVie Inc, Janssen, LabCorp, Pfizer, UCB
Grant/Research Support: AbbVie Inc

Gary R. Lichtenstein, MD

Consultant: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc., Merck & Co., Pfizer Inc., Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc., Shire Plc, Takeda Pharmaceuticals North America, Inc., UCB, Inc., Valeant Pharmaceuticals International, Inc.
Grant/Research Support: Celgene Corporation, Janssen Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Shire Plc, UCB, Inc., Valeant Pharmaceuticals International, Inc.
Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications, Inc.), Luitpold Pharmaceuticals, Inc., McMahon Publishing, Merck & Co., Romark, L.C., Springer Science+Business Media, UpToDate^®
Other/Royalty: Eli Lilly and Company (Data and Safety Monitoring Board), Janssen Pharmaceuticals, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), Pfizer Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), SLACK, Incorporated (Book Royalty), Takeda Pharmaceuticals North America, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania)

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Kayla Messer, Jim Kappler, PhD, Julia Muino.

Designation of Credit

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the post-test and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.